BRAF and melanoma: In addition to identifying NR2F1 as a key molecular driver of drug tolerance in melanoma, Tiago and colleagues have highlighted mTOR inhibition as a promising strategy to delay relapse and provided strong evidence supporting NR2F1 as both a marker and mediator of residual disease in BRAF-mutant melanoma.